Xanomeline-Trospium Bead Composition for Reduced Peripheral Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for schizophrenia and Alzheimer's disease primarily target dopamine and serotonin receptors, leaving negative and cognitive symptoms untreated, and muscarinic receptor agonists like xanomeline face significant side effects due to peripheral receptor activation, hindering their development.
Innovation Solution
An oral pharmaceutical composition comprising xanomeline and trospium beads, specifically sized and formulated to achieve rapid dissolution and controlled release, minimizing peripheral side effects and enhancing tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If xanomeline is used as a muscarinic receptor agonist to treat schizophrenia and Alzheimer's disease, then therapeutic efficacy is improved, but peripheral side effects (GI disturbances, cardiac effects, hypersalivation) increase
Solution Approach 1:
The patent divides the muscarinic receptor system into central (CNS) and peripheral components. By using a selective M1/M4 agonist that preferentially activates central receptors while minimizing peripheral receptor activation, the treatment achieves therapeutic efficacy in the brain while reducing peripheral side effects like GI disturbances, cardiac effects, and hypersalivation.
Solution Approach 2:
The patent introduces a selective agonist as an intermediary substance that preferentially binds to and activates M1 and M4 muscarinic receptor subtypes in the central nervous system. This selective activation serves as a mediator between the administered drug and the therapeutic effect, achieving CNS benefits while avoiding peripheral muscarinic receptor activation that causes side effects.
2Adaptability or versatility
If conventional antipsychotics targeting dopamine and serotonin receptors are used, then positive symptoms are treated, but negative and cognitive symptoms remain untreated
Solution Approach 1:
The patent employs a muscarinic receptor agonist with broad therapeutic potential that can address multiple symptom domains simultaneously. The M1/M4 selective agonist has demonstrated efficacy not only in schizophrenia but also in Alzheimer's disease, Parkinson's disease, depression, and addiction, making it a universal treatment approach for multiple CNS disorders with diverse symptom profiles including negative and cognitive symptoms.
3Ease of operation
If muscarinic receptor agonists are developed to avoid peripheral side effects, then tolerability is improved, but development progress has been limited
Solution Approach 1:
The patent achieves improved tolerability by changing the selectivity parameter of the muscarinic agonist. By designing a compound with preferential affinity for M1 and M4 receptor subtypes over other muscarinic subtypes, the drug maintains central therapeutic effects while minimizing peripheral side effects. This parameter change in receptor selectivity has enabled successful clinical development where previous non-selective agonists failed.
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.